Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1391&sort=award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1390&sort=award_amount" }, "data": [ { "type": "Grant", "id": "12781", "attributes": { "award_id": "75N93023C00024-0-9999-1", "title": "Development of In Vitro Diagnostics for the Detection of SARS-CoV-2", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-06-01", "end_date": "2025-05-31", "award_amount": 4590862, "principal_investigator": { "id": 28682, "first_name": "SCOTT", "last_name": "SCHAUS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2158, "ror": "", "name": "SORRENTO THERAPEUTICS, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the development of promising diagnostics technologies for biothreat pathogens and toxins, as well as pathogens causing emerging and reemerging infectious diseases. Areas of support may focus on improving performance of agnostic nucleic acid sequencing solutions on commercial platforms; methods that improve protein analyte detection; and efforts to improve direct-from-blood or other biofluid detection and identification of microbial infection.", "keywords": [ "Area", "Blood", "COVID-19 detection", "COVID-19 diagnostic", "Coronavirus", "Detection", "Development", "Emerging Communicable Diseases", "Infection", "Methods", "Nucleic acid sequencing", "Performance", "Proteins", "Toxin", "biothreat", "diagnostic technologies", "improved", "in-vitro diagnostics", "microbial", "pathogen" ], "approved": true } }, { "type": "Grant", "id": "8195", "attributes": { "award_id": "75N92021D00008-0-759202100003-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) CLINICAL EVALUATION SERVICES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-21", "end_date": "2021-09-20", "award_amount": 4625250, "principal_investigator": { "id": 23973, "first_name": "MARK", "last_name": "MARINO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has an open solicitation for proposals to provide up to $500 million across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.", "keywords": [ "American", "COVID-19", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 testing", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Contracts", "Department of Defense", "Development", "Device Designs", "Diagnostic tests", "Ensure", "Exhalation", "Funding", "Goals", "Home", "Improve Access", "Laboratories", "Life Cycle Stages", "Modification", "National Institute of Biomedical Imaging and Bioengineering", "Patients", "Performance", "Point of Care Technology", "Privatization", "Program Development", "RADx", "Readiness", "Research", "Saliva", "Sampling", "Seasons", "Sensitivity and Specificity", "Services", "Speed", "Structure", "Technology", "Test Result", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Validation", "Virus", "base", "commercialization", "cost", "design", "detection limit", "flu", "handheld mobile device", "home test", "improved", "innovation", "meetings", "novel", "point of care", "product development", "programs", "research clinical testing", "scale up", "technology development", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "15118", "attributes": { "award_id": "2405483", "title": "Interactive, Individualized Professional Learning for Elementary School Teachers: Enhancing Content and Pedagogical Content Knowledge as a Basis for Improving Practice", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Education and Human Resources (EHR)", "Discovery Research K-12" ], "program_reference_codes": [], "program_officials": [ { "id": 27714, "first_name": "Jennifer", "last_name": "Noll", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": null, "award_amount": 4639444, "principal_investigator": { "id": 31670, "first_name": "Yasemin", "last_name": "Copur-Gencturk", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 2765, "first_name": "Ken", "last_name": "Frank", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 31669, "first_name": "Jiliang", "last_name": "Tang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 152, "ror": "https://ror.org/03taz7m60", "name": "University of Southern California", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Mathematics plays a critical role in students’ career choices as well as their success in STEM fields. Unfortunately, math performance often declines as students’ progress through the grade levels and the aftermath of the COVID19 pandemic has worsened the situation. Research has shown that when teachers have strong content and pedagogical content knowledge that they can provide better quality mathematics instruction to their students and improve student outcomes. The goal of this project is to enhance elementary school teachers’ capacity to improve students’ mathematics learning through a scaled professional development program that uses artificial intelligence (AI) to create a personalized, active learning environment for teachers. The professional development program focuses on key elements of content-specific expertise needed for teaching, such as enhancing teachers’ understanding of the foundational ideas behind numbers and operations concepts that are developed across grade levels, as well as teachers’ understanding of how students learn these concepts and how various instructional tools and practices can improve students’ learning. By creating a professional development that is adaptive to the individualized needs of teachers and is accessible to teachers anywhere and at any time, this work has the potential to change student outcomes at scale. The professional development program utilizes advances in AI to create an inquiry-based learning environment for teachers to enhance their understanding through solving problems of practice. Equipping teachers with the knowledge and skills crucial for quality teaching has the potential to improve mathematics teaching and learning at scale, which has the potential to reduce the opportunity gaps to quality teaching faced by underserved students.<br/><br/>The specific focus of this project is to enhance elementary school teachers’ content and pedagogical content knowledge of numbers and operations using a multiple-AI-agent to guide teachers’ development of a conceptual understanding of the content as well as ways to make the content more accessible to their students. Rather than AI delivering the information, the AI tool will serve as a facilitator to create a learning environment in which teachers meaningfully engage with purposefully developed activities and learn through the process. The research questions the work addresses are: (1) In what ways can advances in AI be incorporated into the AI-based interactive professional development program? (2) How well does the AI-based professional development program enhance teachers’ content and pedagogical content knowledge of numbers and operations? and (3) How well does the AI-based professional development program enhance the quality of mathematics teaching and students learning of numbers and operation? The professional development program and AI tool will be developed through multiple iterations and inputs from several key stakeholders, such as teachers, teacher educators, and content experts. The study will use a mixed methods approach. The effectiveness of the fully developed program on instruction and student learning will be explored through a randomized controlled trial with 200 elementary school teachers. The final version of the program will be made available online. <br/><br/>The Discovery Research preK-12 program (DRK-12) seeks to significantly enhance the learning and teaching of science, technology, engineering, and mathematics (STEM) by preK-12 students and teachers, through research and development of innovative resources, models, and tools. Projects in the DRK-12 program build on fundamental research in STEM education and prior research and development efforts that provide theoretical and empirical justification for proposed projects.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15390", "attributes": { "award_id": "1U19AI181930-01", "title": "RP1: Antigen design and testing of arenavirus and nairovirus", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-07-30", "end_date": "2027-06-30", "award_amount": 4640498, "principal_investigator": { "id": 31991, "first_name": "Robert W", "last_name": "Cross", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 851, "ror": "", "name": "UNIVERSITY OF TEXAS MED BR GALVESTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "– RP1 (Antigen Design and Testing Of Arenavirus And Nairovirus Vaccines) The viral order Bunyavirales contains several high priority human pathogens. Notably, Arenaviridae and Nairoviridae families contain viruses which cause severe hemorrhagic diseases in humans across the world with mortality rates up to 60% and some are associated with significant, long-term sequelae in survivors. Of these, rodent borne arenaviruses – Lassa (LASV), Lujo, Chapare, Guanarito, Junin and Machupo viruses and one tickborne Nairovirus-Crimean-Congo Hemorrhagic Fever Virus- are identified as NIAID Category A pathogens due to ease of dissemination or transmission person-to-person, production of significant morbidity and mortality, the potential for major public health impact, and due to the requirement for special action for public health preparedness. Threats to public health are further heightened by the lack of internationally approved vaccines to address threats of natural epidemics as well as the potential bio-weaponization of these viruses. To address this unmet need, PABVAX RP1 will leverage combined expertise in high-containment virology, immunology, and biological product development, to develop arenavirus and nairovirus research tools and vaccine approaches using prototype members of each viral group which can be adapted across each viral family using a “plug-and-play” approach. Much of the work developing vaccines for these viruses has relied on isolates derived over 40 years ago, recent advances in viral reverse for these viral families is making vaccine testing of emerging isolates more feasible by improving access. Vaccine development for most arenaviruses and nairoviruses has centered on the understanding of the critical role for viral glycoproteins (GP) and nucleoproteins (NP) to drive natural immunity. We have recently successfully engineered a recombinant, stabilized prefusion LASV GPe to act as an antigenic mimic of viral surface displayed GP and found this trimeric GPe alone, co- delivered with NP, or NP subunits alone, can protect guinea pigs against lethal challenge by LASV underscoring the value of these antigens as vaccine components. Subunit vaccines are prime candidates for alternative vaccination approaches like microneedle patches (MNP). MNP coupled antigens and adjuvants directly interact with the potently immunoresponsive cutaneous microenvironments using dissolvable MNPs to elicit robust and long-lasting protective immunity against the target pathogen. The importance of humoral immunity for affording potent protection or treatment against viral infections cannot be understated as evidenced by the recent success using monoclonal antibody therapies to treat Ebola virus disease or COVID-19, yet little is known for the potential for pre-exposure prophylactic (PREP) administration of antibody therapies and what kind of prophylactic windows are possible. In this proposal, we will develop protective protein-based subunit-MNP vaccines, PREP treatment strategies, and recombinant virus tools using prototyped arenaviruses and nairoviruses which will template development of countermeasures against other related Bunyaviridae members.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15704", "attributes": { "award_id": "1P30AG092752-01", "title": "North Texas ADRC", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 32575, "first_name": "CERISE", "last_name": "ELLIOTT", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-15", "end_date": "2030-03-31", "award_amount": 4663946, "principal_investigator": { "id": 26206, "first_name": "IHAB M", "last_name": "HAJJAR", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1215, "ror": "", "name": "UT SOUTHWESTERN MEDICAL CENTER", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "This new application is to establish the North Texas Alzheimer’s Disease Research Center (NT-ADRC) which will serve North Texas, one of the most-populous catchment areas in the country. This application describes how we plan to build a unique and interconnected multidisciplinary center that will create an environment that enables and supports innovative research, training and eventually enhance the care and lives of those dealing with Alzheimer's Disease (AD) and related dementias (ADRD). It is built on a strong foundation of AD and ADRD research and will synergize and connect multiple AD/ADRD investigators and their programs at University of Texas (UT) Southwestern Medical Center, UT Dallas, and UT Arlington. The NT-ADRC will benefit from the strong institutional support to advance AD and ADRD research, our long history of studying cardiometabolic factors, particularly hypertension, in AD/ADRD, our recent expansion of the cutting-edge neuroimaging, informatics, machine learning, and artificial intelligence (ML/AI) capabilities in neurosciences, and the recruitment of multiple key leaders in the Neurocognitive space. The NT-ADRC thematic focus is on examining the roles and mechanisms of hypertension and other cardiometabolic factors in the early phases of AD/ADRD, developing innovative biomarkers for early detection, and identifying related therapeutic targets. We have an exceptional engagement in our diverse communities that is amplified by the participation of Parkland Health and its community ties. We also create novel ways to enhance inclusiveness in ADRD research particularly Lumbar Punctures acceptance and Brain Donation enrollment. These amplify the Center’s abilities to create a highly diverse UDS cohort representative of our diverse population as evidenced by our affiliated studies (Dallas Heart Study and the NIA-funded Post-COVID Neuro-Cognitive Manifestations in Older African Americans). The NT-ADRC Center addresses multiple elements in the National Alzheimer's Project Act (NAPA) and its Implementation Milestones by enabling ongoing and new research in the preclinical and prodromal stages centered around the discovery of novel disease mechanisms underlying the role of hypertension and other cardiometabolic factors in increasing the risk of AD/ADRD; implementing novel ML/AI approaches to biomarker developments; and paving the way for novel therapeutic developments. The NT- ADRC will enhance scientific and clinical collaborations by sharing of biosamples and data with local and national investigators, dissemination of research findings to professional and lay audiences and create education opportunities for researchers, clinicians, learners, and the general North Texas community focused on enhancing caregivers’ education and support. Our commitment to diversity, innovation and rigor to ADRD research will build a new local environment of cutting-edge research and training. It will also position us to make important contributions to the ADRC network and to advance the national agenda towards meeting the NAPA goals.", "keywords": [ "Acceleration", "Action Research", "Address", "African American population", "Alzheimer disease detection", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease related dementia", "Alzheimer&apos", "s disease risk", "Angiography", "Artificial Intelligence", "Awareness", "Behavioral", "Biological Markers", "Brain", "Brain imaging", "COVID-19 neurocognitive sequelae", "Caregivers", "Caring", "Catchment Area", "Clinical", "Cohort Studies", "Collaborations", "Communities", "Community Health Education", "Country", "Coupled", "Data", "Data Science", "Data Set", "Dementia", "Development", "Disease", "Early Diagnosis", "Education", "Elements", "Enrollment", "Environment", "Foundations", "Funding", "Goals", "Health", "Heart", "Hypertension", "Image", "Informatics", "Institution", "Intervention", "Liquid substance", "Machine Learning", "Measures", "Medical center", "Mentors", "Nerve Degeneration", "Neurocognitive", "Neurosciences", "Pathogenesis", "Peripheral", "Persons", "Phase", "Population", "Population Heterogeneity", "Positioning Attribute", "Proteins", "Recording of previous events", "Research", "Research Infrastructure", "Research Personnel", "Resources", "Risk Factors", "Role", "Schools", "Science", "Social Work", "Speech", "Spinal Puncture", "Standardization", "System", "Texas", "Therapeutic Trials", "Training", "Translational Research", "Universities", "Voice", "arterial stiffness", "biobank", "biomarker development", "cardiometabolism", "caregiver education", "caregiving", "cerebrovascular reactivity", "clinical center", "cohort", "community engagement", "community partnership", "data management", "data sharing", "early detection biomarkers", "education research", "health equity", "innovation", "meetings", "multidisciplinary", "neuroimaging", "neuropathology", "new therapeutic target", "next generation", "novel", "novel marker", "novel therapeutics", "outreach", "post-COVID-19", "pre-clinical", "programs", "protein misfolding", "recruit", "repository", "statistics", "success", "synergism", "therapeutic development", "therapeutic target", "tomography", "vascular injury" ], "approved": true } }, { "type": "Grant", "id": "10009", "attributes": { "award_id": "2229983", "title": "Microelectronics and Nanomanufacturing Partnership for Veterans", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Education and Human Resources (EHR)", "Advanced Tech Education Prog" ], "program_reference_codes": [], "program_officials": [ { "id": 692, "first_name": "Virginia", "last_name": "Carter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2026-08-31", "award_amount": 4671964, "principal_investigator": { "id": 11369, "first_name": "Osama", "last_name": "Awadelkarim", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 25828, "first_name": "Richard", "last_name": "Vaughn", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 25829, "first_name": "Juan P", "last_name": "Gonzalez-Gonzalez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 25830, "first_name": "Anthony C Fontes", "last_name": "Sr", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 25831, "first_name": "Seung J", "last_name": "Paik", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 219, "ror": "", "name": "Pennsylvania State Univ University Park", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The United States (U.S.) has been experiencing a semiconductor chip shortage due in part to the pandemic. This shortage has impacted businesses and industry, including automotive, consumer electronics, data science, and cybersecurity to name a few. Efforts are underway to support semiconductor and microelectronics technologies in the U.S., which will require a prepared and diverse skilled technical workforce to support these critical economic engines. A strong nanomanufacturing workforce will enable the U.S. to be competitive in the global economy and will support the U.S. leadership in microelectronics and semiconductor technologies. This project led by the Center for Nanotechnology Education and Utilization at Pennsylvania State University will support members of the U.S. military, veterans, and family members to gain the knowledge, skills, and abilities (KSAs) to move into the semiconductor and microelectronics workforce. Many of these individuals have relevant experience with military technology as members of teams responsible for building mechanical, electrical and communication systems. Veterans without direct military technology experiences also have skills such as teamwork and project management skills that industry recognizes as needed skills within their workforce. \n\nThis project will provide educational opportunities for military personnel, veterans, and family members to gain the KSAs needed to enter the nanomanufacturing workforce. Members of the collaborative include 2-yr and 4-yr institutions, microelectronics companies, and the Global SEMI Trade Association. The project will leverage a successful pilot that involved the U.S. Navy, Tidewater Community College and Norfolk State University, which will be adapted and scaled to involve additional academic institutions and branches of the military. The project will: (1) adapt and implement the content of the pilot and offer a Microelectronics and Nanomanufacturing Certificate Program (MNP) supported by community and technical colleges and universities, (2) continually assess and adjust the content in consultation with industry for skillset needs, (3) work to secure the endorsement of the MNP by departments of veteran services for different military branches, and (4) elevate the role of community and technical college faculty in the delivery of the MNP minimizing the dependence on the research universities. This project is funded by the Advanced Technological Education program that focuses on the education of technicians for the advanced-technology fields that drive the nation's economy.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15547", "attributes": { "award_id": "75N95023D00027-0-759502400002-1", "title": "SECURE PLATFORMS SUPPORT FOR THE N3C DATA ENCLAVE", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-03-21", "end_date": "2024-06-30", "award_amount": 4685560, "principal_investigator": { "id": 26481, "first_name": "BRIAN", "last_name": "ZAVERTNIK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1737, "ror": "", "name": "PALANTIR TECHNOLOGIES, INC.", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C Data Enclave is a secure platform storing harmonized clinical data provided by more than 60 contributing members. The Enclave hosts over 670 million clinical observations on over 6.8 million persons, including over 2.2 million COVID cases, amounting to more than 7.8 billion rows of data. To protect privacy, this data consists only of limited data sets, de-identified data sets, and synthetic data sets; there is no personally identifiable information kept in the Enclave. The Enclave resides in the NCATS Secure Scientific Platforms Environment. The Environment is a specialized cloud-based data aggregation and analytics enclave that can integrate, manage, secure, and analyze any kind of scientific data, and provide secure, controlled access to internal and external collaborators. Within the Environment, multiple NIH ICs, Federal agencies, and Federal task forces integrate, manage, secure, and analyze all types of scientific data using dedicated platforms, and, equally importantly, make that data available in specific and controlled collaborations with each other and with external collaborators.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "5961", "attributes": { "award_id": "3U54AG063546-03S1", "title": "NIA AD/ADRD Health Care Systems Research Collaboratory", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 20408, "first_name": "PARTHA", "last_name": "BHATTACHARYYA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-09-01", "end_date": "2024-06-30", "award_amount": 4695873, "principal_investigator": { "id": 20409, "first_name": "SUSAN L", "last_name": "MITCHELL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 20410, "first_name": "Vincent", "last_name": "Mor", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 222, "ror": "https://ror.org/05gq02987", "name": "Brown University", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "Over five million Americans have Alzheimer's disease (AD) or an AD-related dementia (AD/ADRD). These high- need, high-cost patients are vulnerable to receiving poor quality, uncoordinated care, ultimately leading to adverse health outcomes, poor quality of life, and misuse of resources. As recently concluded by the federally- funded Research Summit on Dementia Care, improving the care of PWD and their CGs is an urgent public health challenge that must be met and informed by high quality evidence. While prior research has elucidated opportunities to improve the care of PWD and their CGs, the adoption of promising interventions has been stymied by the lack of research evaluating their effectiveness when implemented under “real-world” conditions. Pragmatic clinical trials embedded (ePCTs) in healthcare systems (HCS) have the potential to accelerate the translation of evidence-based interventions into clinical practice. Since its inception in 2012, the NIH Common Fund HCS Research Collaboratory has made pivotal contributions towards advancing the conduct of ePCTs. However, as concluded in a 2017 NIA-sponsored conference, ePCTs conducted with PWD and their CGs have unique considerations that merit specific focus. Thus, the overarching objective of this proposal is to build on the model of the NIH Collaboratory to establish the National Institute on Aging (NIA) AD/ADRD Research Collaboratory, co-led by the multiple principal investigators (MPIs), Drs. Vince Mor (Brown University) and Susan Mitchell (Hebrew SeniorLife (HSL)) and co-administered by their respective institutions. The Aims are: 1. To establish the infrastructure of the AD/ADRD Collaboratory, 2. To develop and disseminate guidelines for the conduct of all aspects of ePCTs among PWD and their CGs in partnership with HCS, 3. Enhance research development and investigator capacity to conduct ePCTs in PWD and their CGs within HCS, and 4. To disseminate knowledge and best practices to engage stakeholders in this research. Accomplished investigators from across the nation will lead the following Working Group Cores: 1. Technical and Data (B), J. Bynum, MD, MPH; 2. Regulation and Ethics (C), J. Karlawish, MD; 3. Design and Statistics (D), H. Allore, PhD; 4. Pilot Studies (E), A. Brody, PhD, RN; 5. Patient and CG Reported Outcomes (F), L. Hanson, MD, MPH; 6. Dissemination and Implementation (G), L. Gitlin, PhD/J. Gaugler, PhD; 7. HCS (H): E. Larson, MD, MPH, and Training (I): C. Callahan MD/A. Torke MD. An Administration Core (A) will integrate all critical functions across the Collaboratory. IMPACT: There is an urgent need to improve care provided by HCS for PWD and their CGs. ePCTs conducted are ideally-suited to test the effectiveness of interventions aimed at improving their health outcomes but require specific expertise, methodology, data sources, and industry partnerships. The knowledge, investigative experience, collaborations, and evidence generated by an AD/ADRD Collaboratory has the potential to transform the delivery, quality, and outcomes of care for Americans from all backgrounds with AD/ADRD and their CGs.", "keywords": [ "Acute", "Address", "Adoption", "Aging", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease related dementia", "American", "Assisted Living Facilities", "Caregivers", "Caring", "Clinic", "Clinical Trials", "Cluster randomized trial", "Collaborations", "Conduct Clinical Trials", "Data", "Data Set", "Data Sources", "Dementia", "Development", "Dissemination and Implementation", "Doctor of Philosophy", "Effectiveness", "Effectiveness of Interventions", "Electronic Health Record", "Ethics", "Evidence based intervention", "Foundations", "Funding", "Guidelines", "Health", "Health Maintenance Organizations", "Healthcare Systems", "Home Health Agency", "Infrastructure", "Institution", "Intervention", "Investments", "Joints", "Knowledge", "Lead", "Leadership", "Methodology", "Methods", "Modeling", "National Institute on Aging", "Nursing Homes", "Observational Study", "Outcome", "Patient Care", "Patient-Focused Outcomes", "Patients", "Persons", "Pilot Projects", "Policies", "Population", "Practice Guidelines", "Pragmatic clinical trial", "Principal Investigator", "Public Health", "Public Health Schools", "Quality of life", "Records", "Registries", "Regulation", "Reporting", "Research", "Research Personnel", "Resources", "Subacute Care", "Textbooks", "Time", "Training", "Training Support", "Translations", "United States National Institutes of Health", "Universities", "Work", "care costs", "care outcomes", "clinical practice", "collaboratory", "community living", "cost", "dementia care", "design", "diversity and inclusion", "effectiveness testing", "evidence base", "experience", "hospice environment", "implementation science", "improved", "improved outcome", "industry partner", "knowledge repository", "life time cost", "medical specialties", "multidisciplinary", "novel strategies", "research and development", "sound", "statistics", "symposium", "systems research", "working group" ], "approved": true } }, { "type": "Grant", "id": "15082", "attributes": { "award_id": "4UG3HL164285-02", "title": "1/2 REPRIEVE Extension for Trial Completion", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 10288, "first_name": "Patrice", "last_name": "Desvigne-Nickens", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-05-01", "end_date": "2026-04-30", "award_amount": 4747407, "principal_investigator": { "id": 10289, "first_name": "Pamela Susan", "last_name": "Douglas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 10290, "first_name": "STEVEN K.", "last_name": "GRINSPOON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary-Abstract Globally, cardiovascular disease (CVD) burden is increasing and a major cause of mortality among people with HIV (PWH). However, data are not yet available from large trials on an effective primary CVD prevention strategy for PWH. The ongoing REPRIEVE trial will address this critical knowledge gap, hypothesizing that statin therapy, with pleiotropic effects on LDL, immune activation and inflammatory pathways, will modify traditional and nontraditional risks and prevent major adverse cardiovascular events (MACE) in PWH. REPRIEVE is well-positioned to provide high quality, clinically actionable and generalizable information to shift the current paradigm of HIV care, in alignment with the goals of NHLBI and OAR to reduce CVD and improve the overall health of PWH. REPRIEVE has met major challenges, anticipated for a large trial. 7,770 participants (31% female, 43% Black, 25% Latino) were enrolled from over 100 sites in 12 countries, a diverse, generalizable population. Retention is high, >90%. Endpoint (MACE) are accumulating steadily despite a low median ASCVD risk score of 4.5%, consistent with the hypothesis that nontraditional risks contribute to CVD in HIV. The Mechanistic Substudy has met its goal, enrolling over 800 participants for serial coronary CT angiography (CTA) and immune function. Preliminary baseline data from the substudy support our hypothesis, linking plaque to CVD risk but also independently to IL-6 and Lp-PLA2, key indices of immune function and arterial inflammation that are being targeted in REPRIEVE. Moreover, REPRIEVE is being leveraged to assess statin effects on COVID severity, and long-term effects in PWH, critical unanswered questions for the field. REPRIEVE has executed well over 6 years and is fundamentally strong. However, with a long duration of recruitment and protocol revisions to identify the optimal at-risk group given new guidelines, median duration of follow up is still short at 3.5 years. REPRIEVE needs additional time, projected at 2 years, plus a close out year, to collect necessary MACE to ensure adequate power, analyze, and disseminate this data. The pressing need for data from a large global primary prevention trial has only grown since REPRIEVE was initiated. Completion of the trial will protect the value of the initial NIH investment and honor the commitment to our participants and scientific community to meet the Aims of the trial. This application for the Clinical Coordinating Center (CCC) of the REPRIEVE Extension for Trial Completion focuses on the clinical rationale and coordination of the trial. The Data Coordinating Center (DCC) application focuses on data management, including the coronary CTA data of the Mechanistic Substudy, and the statistical rationale for the trial design.", "keywords": [ "Acquired Immunodeficiency Syndrome", "Angiography", "Antibodies", "Antibody Response", "Arterial Fatty Streak", "Biological Factors", "Black race", "CCL2 gene", "COVID-19", "COVID-19 incidence", "COVID-19 severity", "Cardiac", "Cardiovascular Diseases", "Cardiovascular system", "Caring", "Characteristics", "Clinical", "Coagulation Process", "Communities", "Coronary", "Coronary Arteriosclerosis", "Country", "Data", "Data Coordinating Center", "Diet", "Dyslipidemias", "Enrollment", "Ensure", "Environment", "Epidemiology", "Event", "Female", "Fibrin fragment D", "Funding", "Genes", "Genetic", "Glucose", "Goals", "Guidelines", "HIV", "Health", "Heart failure", "Immune", "Immunoglobulin A", "Immunoglobulin G", "Immunologics", "Infection", "Inflammation", "Inflammatory", "Insulin", "Integration Host Factors", "Interleukin-6", "Investments", "Knowledge", "Latino", "Life Style", "Link", "Lipids", "Liver Dysfunction", "Long-Term Effects", "Low-Density Lipoproteins", "Malignant Neoplasms", "Mediating", "Morphology", "Myositis", "National Heart Lung and Blood Institute", "Outcome", "Participant", "Pathway interactions", "Persons", "Phenotype", "Population", "Populations at Risk", "Positioning Attribute", "Prevention strategy", "Prevention trial", "Primary Prevention", "Proteins", "Proteomics", "Protocols documentation", "Risk", "Risk Factors", "SARS-CoV-2 infection", "Safety", "Serotyping", "Severities", "Site", "Smoking", "Symptoms", "T-Lymphocyte", "Time", "United States National Institutes of Health", "Update", "Viral Load result", "adjudication", "attenuation", "burden of illness", "cardiovascular disorder prevention", "cardiovascular disorder risk", "cardiovascular risk factor", "clinical application", "clinically actionable", "cohort", "coronary computed tomography angiography", "coronary plaque", "data management", "efficacy evaluation", "experience", "follow-up", "high risk", "immune activation", "immune function", "improved", "indexing", "lipoprotein-associated phospholipase A(2)", "monocyte", "mortality", "novel", "oxidized low density lipoprotein", "participant enrollment", "pleiotropism", "predictive marker", "prevent", "primary endpoint", "recruit", "transcriptomics", "trial design" ], "approved": true } }, { "type": "Grant", "id": "7749", "attributes": { "award_id": "75N92019D00033-P00002-759201900074-1", "title": "REDS-IV-P - CENTER FOR TRANSFUSION LABORATORY STUDIES (CTLS) - SARS-CoV-2/COVID-19 STUDIES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-04-01", "end_date": "2021-03-31", "award_amount": 4748941, "principal_investigator": { "id": 23549, "first_name": "MICHAEL Paul", "last_name": "BUSCH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1617, "ror": "", "name": "VITALANT", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1617, "ror": "", "name": "VITALANT", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "This project will focus on key blood safety issues with COVID-19 and further our understanding of SARS-CoV-2 natural history and pathogenesis.", "keywords": [ "2019-nCoV", "Blood", "Blood Transfusion", "COVID-19", "Laboratory Study", "Natural History", "Pathogenesis", "Prevention", "Safety", "Transfusion", "transmission process" ], "approved": true } } ], "meta": { "pagination": { "page": 1391, "pages": 1419, "count": 14184 } } }